Skip to content

Clinical trial of Atorvastatin in Ulcerative Colitis

A randomized, double blind,parallel group, placebo-controlled dose ranging trial of atorvastatin in patients with mild to moderate ulcerative colitis not controlled on 5-Aminosalicylic Acid

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2012/09/003016
Enrollment
64
Registered
2012-09-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Acute Exacerbation of Ulcerative Colitis

Interventions

Intervention1: Atorvastatin: 20 mg once per day for 8 weeks Control Intervention1: Matching Placebo: Single tablet per day for 8 weeks

Sponsors

Post Graduate Institute of Medical Eduation and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with established diagnosis of ulcerative colitis on endoscopy Suffering from moderately severe acute ulcerative colitis having a Mayo Score between 4 to 10 at the time of enrollment despite treatment with 5-ASA Patients on stable dose of 5-ASA for the last 4 weeks Patients willing to provide written informed consent

Exclusion criteria

Exclusion criteria: Patients with severe ulcerative colitis (Mayo Score more than 11) Patients with Crohns Disease Use of immunosuppressive drugs within previous 90 days Patients with evidence of infectious colitis Patients already on lipid lowering treatment Pregnant or nursing women Patients with significant hepatic or renal disease, congestive heart failure, or any major significantly uncontrolled co-morbidity Patients who have participated in any other clinical trial during last 30 days History of allergy, hypersensitivity or any contraindications to statins

Design outcomes

Primary

MeasureTime frame
Response to therapy was defined as more than 1 point decrease in any 2 sub-scores of Partial Mayo Score for disease activity at any follow-up visit. Non-responders were defined as no change or less than 1 point change in any 2 subscores of Partial Mayo Scoare for disease activity at any follow-up visit. Patients with an increase of more than 1 point in any 2 sub-scores of partial Mayo were withdrawn from the study Timepoint: 0, 4 and 8 weeks after randomization

Secondary

MeasureTime frame
Change in lipid profile from baseline Timepoint: 0, 4 and 8 weeks after randomization;Percentage of patients achieving remission defined as Mayo score of 2Timepoint: 0, 4 and 8 weeks after randomization

Countries

India

Contacts

Public ContactDr Puneet Dhamija

Post Graduate Institute of Medical Education and Research

debhota@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026